Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Formulation

0.2 ?m filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <1.0 EU/mg of the protein. (<0.1 pg/?g of the protein) as determined by the LAL test.

Preparation

The GoInVivo? antibody was purified by affinity chromatography.

Concentration

The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL.

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C. This GoInVivo? solution contains no preservative; handle under aseptic conditions.

Application

FC - Quality tested
Block - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 ?g per million cells in 100 ?L?volume or 100 ?L?of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

For in vivo and in vitro applications, we recommend to perform a pilot experiment to determine the optimal concentration to use for each particular experiment.

Application Notes

GoInVivo? products are guaranteed to be pathogen-free based on the IDEXX BioResearch IMPACT test via PCR. For a full listing of pathogens tested, visit the GoInVivo? Webpage.　

Additional reported applications (for the relevant formats) include: immunofluorescence⁴ and blocking^6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections^{11, 12}.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)

1. Maier H, et al. 2007. J. Immunol. 178:2714.
2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
4. Grabie N, et al. 2007. Circulation 116:2062. (IF)
5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
12. Grabie N, et al. 2007. Circulation 116:2062-71. (IHC)
13. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed

Product Citations

1. Bazan-Peregrino M, et al. 2021. J Immunother Cancer. 9:. PubMed
2. Chen H, et al. 2022. J Immunother Cancer. 10:. PubMed
3. Li D, et al. 2021. Mol Cancer Ther. 20:1926. PubMed
4. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
5. Jaynes JM, et al. 2020. Sci Transl Med. 12:00. PubMed
6. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
7. Janela B, et al. 2019. Immunity. 50:1069. PubMed
8. Wang C, et al. 2018. Sci Transl Med. 10. PubMed
9. Yamazaki K, et al. 2022. Sci Rep. 12:3242. PubMed

RRID

AB_2566281 (BioLegend Cat. No. 124328) AB_2566282 (BioLegend Cat. No. 124329) AB_2566283 (BioLegend Cat. No. 124330) AB_2566092 (BioLegend Cat. No. 124325) AB_2566093 (BioLegend Cat. No. 124326) AB_2566094 (BioLegend Cat. No. 124327)